What diseases does Mobotinib/Mobotinib mainly treat?

莫博赛替尼/莫博替尼（Mobocertinib）是一种专门针对EGFR外显子20插入突变的口服酪氨酸激酶抑制剂（TKI）。这类突变是一种在非小细胞肺癌（NSCLC）患者中较少见但临床挑战性较高的基因异常，约占所有EGFR突变的4%至12%。传统的EGFR-TKI如吉非替尼或奥希替尼对这类突变疗效甚微，而莫博赛替尼则是为克服这一治疗盲区而开发的靶向药物。

目前，莫博赛替尼被美国FDA加速批准用于治疗那些既往接受过铂类化疗后病情仍进展的晚期或转移性NSCLC患者，且肿瘤携带EGFR外显子20插入突变。这种适应症的确立使得莫博赛替尼成为首个专门获批用于该特定突变的EGFR-TKI药物，为这类患者提供了精准治疗的新选项。

EGFR exon 20 insertion mutations cause conformational changes in the EGFR protein, making it difficult for traditional TKIs to bind. The molecular structure of mobosetinib is specially designed to adapt to this mutant conformation, so it has higher affinity and inhibitory activity. Except for its clear positioning in the field of lung cancer treatment, there is currently no strong evidence that this drug is suitable for other EGFR mutation-related tumors.

由于这类突变的患者在常规治疗中面临疗效不佳与复发风险高的双重挑战，莫博赛替尼的应用填补了EGFR突变靶向治疗的空白。 Its successful launch is not only a milestone, but also promotes the in-depth development of personalized treatment concepts targeting rare genetic mutations in the treatment of lung cancer. In the future, with further research on the mechanism of exon 20 insertion mutations, this drug may be included in more combination treatment strategies, especially in the context of immunotherapy or new targeted drugs, to further improve overall survival and quality of life.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib